Covid-19 roundup: Did insiders cash in on positive news report about Gilead before publication?
A series of bullish trades on Gilead options just before the release of a favorable news story is raising questions among regulatory experts, Reuters reported.
On April 16, just hours before STAT published anecdotes from a Chicago hospital that served as one of the clinical sites to test Gilead’s remdesivir in Covid-19 patients, the California-based company’s shares were trading at around $75. Four large blocks of options were purchased for about $1.5 million each, betting that the stock would rise beyond that to as much as $87.5 by mid-August.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 86,300+ biopharma pros reading Endpoints daily — and it's free.